ABM Respiratory Care lands $20M debt facility from Trinity Capital
What's the deal? ABM Respiratory Care, a Minnesota-based medical technology company, has secured a $20 million growth capital commitment from Trinity CapitalDealroom has a profile for this one. Try Dealroom →. The debt financing will fund commercial expansion, market growth, and product innovation, the company said on October 20.
What does the company do? Founded in 2017, ABM develops respiratory care systems for hospital and home use. Its FDA-cleared BiWaze platform includes Clear, which delivers oscillating lung expansion therapy, and Cough, which assists patients with an ineffective cough to clear secretions.
Why now? The facility follows ABM's $14.8 million Series B in June 2025, which targeted US sales and clinical research for BiWaze Clear. The company launched its BiWaze Cough product in Canada in August 2025, signalling continued market expansion.
What's the endgame? ABM wants to widen access to its therapies while advancing its Arc Connect digital health platform, which tracks therapy use and patient engagement for care teams. "Our partnership with Trinity Capital provides additional capital and flexibility to expand our commercial reach," said chief executive officer Greg Miller.
Who's backing it? Trinity Capital, a Phoenix-based alternative asset manager listed on the NYSE, led the financing through its Healthcare & Life Sciences vertical. It has deployed more than $6.2 billion across over 490 investments since 2008.
The signal: The deal fits Trinity's pattern of backing medical-device firms moving toward commercialization. It is debt-style growth capital, not a new equity round — its payoff hinges on whether ABM converts the money into wider adoption and measurable sales.
Read more: marketscreener.com
Image credit: Generated with Gemini
